Article
Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer.
Cancer discovery - 9 Jan 2023
Yaeger Rona, Mezzadra Riccardo, Sinopoli Jenna, Bian Yu, Marasco Michelangelo, Kaplun Esther, Gao Yijun, Zhao HuiYong, Paula Arnaud Da Cruz, Zhu Yingjie, Perez Almudena Chaves, Chadalavada Kalyani, Tse Edison, Chowdhry Sudhir, Bowker Sydney, Chang Qing, Qeriqi Besnik, Weigelt Britta, Nanjangud Gouri J, Berger Michael F, Der-Torossian Hirak, Anderes Kenna, Socci Nicholas D, Shia Jinru, Riely Gregory J, Murciano-Goroff Yonina R, Li Bob T, Christensen James G, Reis-Filho Jorge S, Solit David B, de Stanchina Elisa, Lowe Scott W, Rosen Neal, Misale Sandra
Abstract excerpt
With the combination of KRASG12C and EGFR inhibitors, KRAS is becoming a druggable target in colorectal cancer. However, secondary resistance limits its efficacy. Using cell lines, patient-derived xenografts, and patient samples, we detected a heterogeneous pattern of putative resistance alterations expected primarily to prevent inhibition of ERK signaling by drugs at progression. Serial analysis of patient blood...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.